NanOlogy

Executive Summary

NanOlogy is a private biotechnology company developing a novel intratumoral drug delivery platform, Purcision™, which generates large surface area microparticles (LSAMs) of pure drug. This approach aims to concentrate chemotherapy directly within solid tumors, enhancing efficacy while minimizing systemic toxicity. The company's lead programs target various solid tumor indications, leveraging LSAMs to achieve sustained local drug release. NanOlogy's technology has the potential to address significant unmet needs in oncology by improving the therapeutic index of approved and investigational agents. While still in early stages with limited public data, the platform's differentiation and broad applicability warrant close monitoring.

Upcoming Catalysts (preview)

• Q2 2026Initiation of first-in-human Phase 1 trial for lead LSAM candidate40% success
• Q3 2026Presentation of preclinical efficacy and safety data at major oncology conference70% success
• TBDStrategic partnership or licensing deal with larger pharma30% success